Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Regeneron Pharmaceuticals Trading Down 0.6 %
NASDAQ:REGN opened at $1,039.11 on Wednesday. The firm has a market cap of $114.50 billion, a P/E ratio of 30.70, a PEG ratio of 2.14 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock’s 50 day simple moving average is $960.33 and its 200-day simple moving average is $939.67. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $1,052.34.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on REGN
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. West Paces Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $28,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- What Are Trending Stocks? Trending Stocks Explained
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- What is the Australian Securities Exchange (ASX)
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.